FREQUENCIES OF GSTP1( Ile105Val) POLYMORPHISM AND ITS ASSOCIATION WITH CML IN SUDANESE PATIENTS

Journal Title: European Journal of Biomedical and Pharmaceutical Sciences - Year 2017, Vol 4, Issue 10

Abstract

Background: Glutathione S-transferases (GSTs) are enzymes belong to phase II metabolic isozymes, best known for their ability of detoxification of xenobiotic. Several studies reported that gene Polymorphisms within GSTs family conferred a significant association with increased risk of CML. There is no published data about the association of gene polymorphism of these enzymes to CML Sudanese patient’s, So the present study aimed to find out if there was any association between GSTP1 gene polymorphism and CML in Sudanese patients. Materials and methods: This was case control study conducted between January 2016 and June 2017 in which a total of 115 patients with chronic myeloid leukaemia attended the Radiation and Isotope Centre-Khartoum and 104 un related apparently healthy individual as control group were involved. DNA extracted from collected EDTA venous blood samples and analysed by RFLP (Restriction fragments length polymorphism) to detect the presence of GSTP1 (Il105Val). Results: A total of 58.2% (67) of CML patients had heterozygous (Ile/Val) type of GSTP1 Ile105Val polymorphism, 4.35% (5) patients had the homozygous type (Val/ Val) and 37.3% (43) had the wild genotype of GSTP1 (Ile / Ile). In contrast there were 40.3% (42) of the control group with heterozygous (Ile/Val) type, 1.9% (2) with homozygous type (Val/ Val) and 57.6% (60) with wild genotype of GSTP1 (Ile / Ile). GSTP1 Ile105Val polymorphism frequency was found to be significantly elevated in patient with CML 62.6% (72) compared to control group 42.3% (44) (OR = 2.28, 95% confidence interval (CI) 1.33–3.91, p value = 0.002). Discussion and Conclusion: GSTP1 Ile105Val polymorphism was found to be significantly elevated in patient with CML and were associated with CML development and progression, also CML patients in advanced phase (accelerated and blast crisis) had higher frequency of GSTP1 Ile105Val polymorphism compared to chronic phase and this was agreed with most of the published studies.

Authors and Affiliations

Abdel Rahim Mahmoud Muddathir

Keywords

Related Articles

DEVELOPMENT OF HENOCH-SCHONLEIN PURPURA NEPHRITIS AND MIGRATORY POLYARTHRITIS IN A PATIENT WITH IG A NEPHROPATHY

Henoch-Schonlein purpura is a type of systemic vasculitis characterized by deposition of IgA on the vascular wall. Skin, joints, kidney, gastrointestinal tract and other organs may be affected. In this paper we present a...

AWARENESS OF SMOKING-ASSOCIATED HEALTH RISKS AMONG MALE’S HIGH SCHOOLS STUDENTS IN WEST GAZA CITY

Background: Cigarette smoking is one of the main causes of preventable global death. More than 7 million people died as a result smoking and exposure to smokers. Smoking causes many serious cardiovascular and respiratory...

TOTAL QUALITY MANAGEMENT PRACTICES IN PHARMACEUTICAL INDUSTRY

Quality management is a boom in Indian pharmaceutical area and is one such approach along with government regulatory requirements. TQM improves quality and performance in pharmaceutical products and meet customer expecta...

THE PERCENTAGE AND CAUSATIVE AGENTS OF HBV INFECTION IN JORDAN

Hepatitis B is a serious liver infection caused by the hepatitis B virus. For some people, hepatitis B infection becomes chronic, meaning it lasts more than six months. Hepatitis B is a common global health problem and i...

PREVALENCE OF HEARING IMPAIRMENTS IN DIFFERENT AGE GROUPS OF ELURU, WEST GODAVARI DISTRICT, A.P.

Current human studies are indicating different hearing problems are common among general public. Hearing problems are projected to become among the top ten disabilities according to the WHO in the near future. Here we de...

Download PDF file
  • EP ID EP629057
  • DOI -
  • Views 175
  • Downloads 0

How To Cite

Abdel Rahim Mahmoud Muddathir (2017). FREQUENCIES OF GSTP1( Ile105Val) POLYMORPHISM AND ITS ASSOCIATION WITH CML IN SUDANESE PATIENTS. European Journal of Biomedical and Pharmaceutical Sciences, 4(10), 37-40. https://europub.co.uk/articles/-A-629057